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Interleukin-5 (IL-5) levels were significantly higher in vaginal washing fluids from patients with cervical
carcinoma than in those from patients with carcinoma in situ and controls. Tumor necrosis factor alpha levels
did not differ among the three groups. Detection of IL-5 in cervical secretions may be a useful marker for
evaluating aggressive local immune response in cervical carcinoma.
Cellular immune response mediated by cytokines is the main
defense against tumors related to cervical carcinogenesis. Pre-
vious studies have suggested that decreased T helper 1 (Th1)
and increased Th2 responses are associated with cervical car-
cinogenesis (2, 3, 5, 6, 8). However, Th1 and Th2 cytokines,
such as interleukin-1 (IL-1), IL-10, IL-12, tumor necrosis
factor alpha (TNF-), and transforming growth factor beta,
were elevated in cervicovaginal washings from patients with
cervical carcinoma (12). Another study reported that the con-
centrations of TNF- and IL-10 were increased in cases of
cervical intraepithelial neoplasia (1). Although each study was
different in terms of increased cytokine profiles, the results
reveal that both Th1 and Th2 cytokines are increased in cer-
vical carcinoma, which differs from previous reports of a shift
toward a Th2 cytokine pattern during cervical carcinogenesis.
To date, most studies have focused on the cytokine profiles
of the systemic immune response by analysis of peripheral
blood. This study was designed to evaluate the cytokine secre-
tion profiles for the Th2 cytokine IL-5 and the Th1 cytokine
TNF- in cervicovaginal secretions. In addition, we aimed to
verify whether the levels of cytokines were related to eosino-
phil counts and human papillomavirus (HPV) DNA titers.
Women with abnormal cervical cytology who had been re-
ferred to the Women’s Cancer Clinics of Severance Hospital
between May 2006 and November 2006 were included. For all
women, a cervical biopsy and HPV sampling were performed.
Informed consent was obtained from each patient prior to
enrollment. We recruited women who were diagnosed histo-
logically with cervical carcinoma (n  20) or carcinoma in situ
(CIS) of the uterine cervix (n  6). Women histologically
diagnosed with chronic nonspecific inflammation were re-
cruited for the control group (n  10) (Table 1).
For cervicovaginal sample collection, all individuals lay in
the supine position in a gynecological examination chair. Vagi-
nal wash samples were collected by instilling 5 ml of phos-
phate-buffered saline, and approximately 3 ml was recovered
by aspiration. Due to the presence of microbiota, a protease
inhibitor cocktail was added (10 mM EGTA, 150 mM NaN3,
0.01% [wt/vol] leupeptin [Sigma, St. Louis, MO], 0.02 M Pe-
fabloc [Boehringer Mannheim, Indianapolis, IN]). IL-5 and
TNF- levels were measured using a commercially available
human enzyme-linked immunosorbent assay kit (Biosource In-
ternational, Inc., Camarillo, CA), according to the manufac-
turer’s instructions. Cervical samples for HPV detection and
typing were taken by a cervical sampler (Digene Corporation),
and HPV DNA titers were measured by the Hybrid Capture 2
HPV DNA test (Digene Corporation, Gaithersburg, MD).
HPV genotyping was performed with HPVDNAChip, a PCR-
based DNA microarray system provided by Microarray Center,
Biomedlab Co. (Seoul, South Korea). Peripheral venous blood
samples were collected from patients with cervical carcinoma.
A differential leukocyte count was performed with a Sysmex
XE-2100 analyzer.
The cytokine data were presented as medians and interquar-
tile ranges. The nonparametric Kruskal-Wallis test was used to
assess the difference in cytokine levels between groups. Inter-
group comparisons were evaluated by Dunn multiple-compar-
ison tests. Correlations between the levels of cytokine in each
group and eosinophil counts and HPV DNA titers were deter-
mined by the Spearman correlation coefficient. The statistical
tests and graphing were performed using Prism 4 Windows
software (GraphPad, Inc., San Diego, CA). P values of 0.05
were considered to be statistically significant.
The median IL-5 concentrations in the cervical carcinoma,
CIS, and control groups were 25.50 pg/ml (interquartile range,
14.25 to 54.25 pg/ml), 12.50 pg/ml (10.50 to 19.00 pg/ml), and
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TABLE 1. Demographic and clinical characteristics of patients in
the control, CIS, and cervical carcinoma groups
Group (no. of patients) Median age (yr)(range)
% with HPV infection
Total Types 16and 18
Control (10) 40.0 (28–58) 70 0
CIS (6) 44.5 (36–52) 100 66
Carcinoma (20) 55.0 (33–87) 100 50
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10.00 pg/ml (7.00 to 14.50 pg/ml), respectively. IL-5 levels dif-
fered between groups (P  0.001). The IL-5 concentrations in
women with cervical carcinoma were significantly higher than
those in the controls (P  0.001) (Fig. 1). The median TNF-
concentrations in the cervical carcinoma, CIS, and control
groups were 6.0 pg/ml (interquartile range, 2.25 to 8.00 pg/ml),
5.50 pg/ml (5.00 to 7.25 pg/ml), and 4.00 pg/ml (2.50 to 9.25
pg/ml), respectively. There were no significant differences in
TNF- concentration between groups (P  0.716). For the
cervical carcinoma, CIS, and control groups, the median ratios
of IL-5/TNF- were 5.23 (interquartile range, 2.20 to 12.88),
2.29 (1.83 to 2.74), and 2.02 (1.25 to 3.05), respectively. The
ratio of IL-5/TNF- had a tendency to increase according to
the stage of the cervical lesion. However, there were no sig-
nificant differences between groups (P  0.061). IL-5 concen-
tration showed no significant correlation with TNF- concen-
tration in the cervical carcinoma group (r  0.249 and P 
0.487), the CIS group (r 0.754 and P 0.086), or the control
group (r  0.128 and P  0.590). A positive correlation was
found between eosinophil counts and IL-5 concentrations in
women with cervical carcinoma (r  0.539 and P  0.026). In
contrast, TNF- concentrations did not correlate with eosino-
phil counts (r  0.011 and P  0.966) (Fig. 2). There was no
correlation between HPV DNA titers and IL-5 or TNF- con-
centrations in patients with cervical carcinoma or CIS (r 
0.297 and P  0.283 or r  0.191 and P  0.496, respectively).
In our study, IL-5 concentrations were significantly higher in
women with cervical carcinoma than in women with CIS or
controls. TNF- concentrations also tended to be higher in
women with cervical carcinoma than in women with CIS or
controls. Although our observation of cytokine correlations at
different stages does not show a shift to the Th2 cytokine as
reported previously, the ratios of IL-5/TNF- tended to in-
crease with the cervical lesion stages. These results indicate
that the Th2 immune response in cervical carcinoma is rela-
tively dominant.
The presence of an eosinophil infiltrate may be indicative of
a less effective antitumor immune response (7, 10, 13). In
addition, a dominant Th2 immune response might explain the
poor clinical outcomes seen in cervical carcinoma patients with
an eosinophilic tumor infiltrate (14). In this study, the higher
levels of IL-5 in patients with cervical carcinoma than in those
with CIS or controls suggest that the Th2 immune response is
dominant in cancer tissue. The positive correlations between
concentrations of IL-5 in cervicovaginal washings and eosino-
phil counts in peripheral blood samples suggest that IL-5 may
promote eosinophil growth and activation, thereby inducing
tissue infiltration in the tumor. Eosinophil counts could be
elevated in peripheral blood because of this imbalance in the
immune response.
The decreased Th1 cytokines, such as IL-2 and IFN-, and
the increased Th2 cytokines, such as IL-4 and IL-10, were
demonstrated to occur in the peripheral blood samples of
women infected by HPV types 16 and 18 (9). Persistent high-
risk HPV infection and increased viral loads have been shown
to be correlated with high-grade cervical intraepithelial neo-
plasia and invasive cancer in previous studies (11, 15). In the
present study, there were cases of high-risk HPV infection in
women with cervical carcinoma and CIS. However, HPV DNA
titers did not show significant correlation with cytokine levels.
The subjects of this study were classified according to their
pathological diagnosis based on cervical biopsy. All controls
had a chronic nonspecific inflammation. Even though histolog-
ical diagnosis of chronic nonspecific inflammation is so preva-
lent that it should be considered the norm for parous women
of reproductive age, inflammatory reaction might affect cervi-
FIG. 1. Distribution of IL-5 (pg/ml) concentrations in cervicovagi-
nal washings from the control (n  10), CIS (n  6), and cervical
carcinoma (n  20) groups. Estimated concentrations are plotted for
each sample. Median levels and interquartile ranges are indicated. In
women with cervical carcinoma, those with CIS, and the controls, the
median IL-5 concentrations were 22.50 pg/ml (interquartile range,
14.25 to 54.25 pg/ml), 12.50 pg/ml (10.50 to 19.00 pg/ml), and 10.00
pg/ml (7.00 to 14.50 pg/ml), respectively. Those in women with cervical
carcinoma were significantly higher than those in controls (P  0.001;
Kruskal-Wallis test followed by Dunn’s multiple-comparison test). ,
P  0.001; NS, no significance.
FIG. 2. Correlation between eosinophil counts and IL-5 (A) and TNF- (B) in the cervical carcinoma group. A positive correlation was found
between eosinophil counts and IL-5 in women with cervical carcinoma (n  17) (r  0.539 and P  0.026). No correlation was observed between
eosinophil counts and TNF- (r  0.011 and P  0.966).
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cal cytokine secretion (4). Therefore, the lack of significant
differences in cytokine concentrations between patients with
CIS and controls may be due to nonspecific, non-HPV-related
infection.
In conclusion, our results indicate that the Th2 immune
response is more active than the Th1 immune response in
cervical carcinoma. In addition, cervical IL-5 concentrations in
cervical carcinoma show statistically positive correlations with
peripheral eosinophil counts. Therefore, detection of IL-5 in
cervicovaginal secretions may be a useful marker for evaluating
aggressive local and peripheral immune responses in cervical
carcinoma.
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